Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Negative Breast Carcinoma”

1,412 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,412 results

Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Testing effectiveness (Phase 2)Study completedNCT02258451
What this trial is testing

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Bayer 283
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Not applicableActive Not RecruitingNCT04370522
What this trial is testing

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 32
Large-scale testing (Phase 3)Looking for participantsNCT07281833
What this trial is testing

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

Who this might be right for
Breast CancerHR-positive Breast CancerAdvanced Breast Cancer+2 more
West German Study Group 250
Testing effectiveness (Phase 2)Ended earlyNCT04738292
What this trial is testing

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Who this might be right for
ER-positive Breast CancerHER2-negative Breast CancerMetastatic Cancer
University of Wisconsin, Madison 11
Large-scale testing (Phase 3)UnknownNCT02383030
What this trial is testing

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 156
Testing effectiveness (Phase 2)UnknownNCT05400993
What this trial is testing

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

Who this might be right for
Breast Cancer
Shengjing Hospital 59
Not applicableStudy completedNCT06003114
What this trial is testing

Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Who this might be right for
Breast Cancer
Pfizer 472
Testing effectiveness (Phase 2)Ended earlyNCT05180006
What this trial is testing

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 33
Testing effectiveness (Phase 2)Looking for participantsNCT04115306
What this trial is testing

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Phoenix Molecular Designs 61
Testing effectiveness (Phase 2)Looking for participantsNCT04333706
What this trial is testing

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

Who this might be right for
BreastMetastaticTriple Negative+2 more
University of Southern California 65
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Large-scale testing (Phase 3)Looking for participantsNCT02535221
What this trial is testing

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Who this might be right for
Breast Cancer
Peking University 234
Testing effectiveness (Phase 2)Active Not RecruitingNCT04762979
What this trial is testing

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast CancerPIK3CA Mutant Metastatic Breast Cancer
Marina N Sharifi 44
Early research (Phase 1)Looking for participantsNCT06120283
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+6 more
BeOne Medicines 399
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Testing effectiveness (Phase 2)Looking for participantsNCT06375707
What this trial is testing

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 144
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Load More Results